Fund of the week: A healthy bio-tech fund
The continual need for new drugs is never going to go away. That's why this bio-tech trust fund is a safe bet for the long term.
The International Biotechnology Trust (LSE: IBT) is in a long-term bull run, manager David Pinniger tells Fund Strategy. Rapidly developing technology and the continual need for new drugs are the key drivers. But it's the level of merger and acquisition activity in the sector that is particularly exciting right now. "There is a lot of money being spent at the moment, especially with the large pharma groups buying early stage companies."
The £92.3m trust trades at a 12.7% discount to its net asset value (its underlying assets), but has outperformed the FTSE World index in recent years, and returned 27.4% over three years. Most of the fund is invested in America, with 17% in Europe and 5% in Israel.
Biotech is risky. Drug development is a long-winded and costly process where much can go wrong. So Pinniger consults a range of people, including medical professionals, before making investment decisions. The portfolio is kept diverse in order to minimise volatility; mature firms account for the biggest positions with smaller, unquoted outfits getting smaller representations. Even so, Pinniger advises investors to take a long-term view: "Buy a bit of the International Biotechnology Trust, forget about it and come back in ten years. Even with a few bumps, we should have done better thanthebroader market."
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
While big pharma' is viewed as a safe haven, government spending cuts will have an impact. But Investors Chronicle notes that the trust is still managing to outperform, and reckons it should continue to benefit from compelling valuations in the sector.
Contact: 020-7421 7070.
International Biotechnology Trust top ten holdings
Cadent | 6.1% |
Amgen | 6% |
Pharmasset | 5.4% |
Teva Pharmaceutical | 5% |
Gilead Sciences | 4.5% |
Insulet Corp | 4.2% |
Shire | 3.9% |
Celgene Corp | 3.5% |
Micromet | 3.5% |
EUSA | 3.3% |
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Starling Bank to use AI to help you with your money - how will it work?
Starling Bank is using AI to show customers how their daily spending is impacting their bank balance, we analyse if the tool is offering anything new and if it can improve your finances.
-
From old clocks to vintage dolls worth thousands – are you sitting on a fortune in your attic?
Many of us are guilty of hoarding things in the loft, but, from coins and vintage jewellery to war memorabilia, your attic could hold items worth thousands of pounds. We look at how much they could sell for